Glucagonoma Pancreatic Neuroendocrine Tumor Treated With 177Lu DOTATATE Induction and Maintenance Peptide Receptor Radionuclide Therapy

被引：11
|
作者：
Makis, William [1 ]
McCann, Karey [1 ]
Riauka, Terence A. [1 ]
McEwan, Alexander J. B. [1 ]
机构：
[1] Cross Canc Inst, Dept Diagnost Imaging, Edmonton, AB T6G 1Z2, Canada
来源：
CLINICAL NUCLEAR MEDICINE | 2015年 / 40卷 / 11期
关键词：
PRRT; Lu-177; DOTATATE; lutetium; glucagonoma; necrolytic migratory erythema;
D O I：
10.1097/RLU.0000000000000891
中图分类号：
R8 [特种医学]; R445 [影像诊断学];
学科分类号：
1002 ; 100207 ; 1009 ;
摘要：
A 56-year-old man presented with a history of 2 prior resections of a recurrent pancreatic glucagonoma in the past 4 years. Workup revealed new liver and abdominal nodal metastases with a rising serum glucagon level. He was started on peptide receptor radionuclide therapy with Lu-177 DOTATATE, and his disease stabilized, while his glucagon levels decreased and also stabilized. After 4 induction and 2 maintenance cycles, he remains progression free for 23 months.
引用
收藏
页码：877 / 879
页数：3
相关论文
共 50 条
  • [31] Radiation precautions for inpatient and outpatient 177Lu-DOTATATE peptide receptor radionuclide therapy of neuroendocrine tumours
    Levart, D.
    Kalogianni, E.
    Corcoran, B.
    Mulholland, N.
    Vivian, G.
    [J]. EJNMMI PHYSICS, 2019, 6 (1)
  • [32] 177Lu-DOTATATE Peptide Receptor Radionuclide Therapy: Dose Response in Small Intestinal Neuroendocrine Tumors
    Jahn, Ulrika
    Ilan, Ezgi
    Sandstrom, Mattias
    Garske-Roman, Ulrike
    Lubberink, Mark
    Sundin, Anders
    [J]. NEUROENDOCRINOLOGY, 2020, 110 (7-8) : 662 - 670
  • [33] Radiation precautions for inpatient and outpatient 177Lu-DOTATATE peptide receptor radionuclide therapy of neuroendocrine tumours
    D. Levart
    E. Kalogianni
    B. Corcoran
    N. Mulholland
    G. Vivian
    [J]. EJNMMI Physics, 6
  • [34] Peptide Receptor Radionuclide Therapy (PRRT) with 177Lu-DOTATATE (177Lu) Is Effective and Safe in Patients with Pretreated Metastatic Neuroendocrine Tumors: Data from Spanish SEPTRALU Registry
    Bello, P.
    Jimenez-Fonseca, P.
    Percovich, J. C.
    Anido Herranz, U.
    Gajate, P.
    Castellon, M.
    Estorch, M.
    Gonzalez, E.
    Field, C.
    Garcia Alonso, P.
    Carmona-Bayonas, A.
    Mitjavila, M.
    [J]. NEUROENDOCRINOLOGY, 2019, 108 : 198 - 198
  • [35] Peptide Receptor Radionuclide Therapy (PRRT) with 177Lu-DOTATATE; Differences in Tumor Dosimetry, Vascularity and Lesion Metrics in Pancreatic and Small Intestinal Neuroendocrine Neoplasms
    Jahn, Ulrika
    Ilan, Ezgi
    Sandstrom, Mattias
    Lubberink, Mark
    Garske-Roman, Ulrike
    Sundin, Anders
    [J]. CANCERS, 2021, 13 (05) : 1 - 15
  • [36] Long-Term Outcomes of Submaximal Activities of Peptide Receptor Radionuclide Therapy with 177Lu-DOTATATE in Neuroendocrine Tumor Patients
    Minczeles, Noemie S.
    de Herder, Wouter W.
    Feelders, Richard A.
    Verburg, Frederik A.
    Hofland, Johannes
    Brabander, Tessa
    [J]. JOURNAL OF NUCLEAR MEDICINE, 2023, 64 (01) : 40 - 46
  • [37] Neuroendocrine Tumor Therapy: 177Lu-DOTATATE
    Mittra, Erik S.
    [J]. AMERICAN JOURNAL OF ROENTGENOLOGY, 2018, 211 (02) : 278 - 285
  • [38] [177Lu]Lu-DOTATATE peptide receptor radionuclide therapy–associated myeloid neoplasms: insights from the WHO pharmacovigilance database
    Jonathan Vigne
    Basile Chrétien
    Anne-Laure Bignon
    Karine Bouhier-Leporrier
    Charles Dolladille
    [J]. European Journal of Nuclear Medicine and Molecular Imaging, 2022, 49 : 3332 - 3333
  • [39] Investigating intrinsic radiosensitivity biomarkers to peptide receptor radionuclide therapy with [177Lu]Lu-DOTATATE in a panel of cancer cell lines
    Delbart, Wendy
    Ghanem, Ghanem E.
    Karfis, Ioannis
    Flamen, Patrick
    Wimana, Zena
    [J]. NUCLEAR MEDICINE AND BIOLOGY, 2021, 96-97 : 68 - 79
  • [40] Clinical peptide receptor radionuclide therapy: Kit preparation of 90Y, 177Lu, and 111In DOTATATE
    Ballinger, J. R.
    Tan, Y.
    Allen, S. J.
    Lewington, V. J.
    [J]. EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2013, 40 : S425 - S425
12345